Brinkley Garrett J, Fang Andrew M, Rais-Bahrami Soroush
Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
Department of Urology, The University of Alabama at Birmingham, Birmingham, AL, USA.
Ther Adv Urol. 2022 May 13;14:17562872221096386. doi: 10.1177/17562872221096386. eCollection 2022 Jan-Dec.
The decision whether to undergo prostate biopsy must be carefully weighed. Nomograms have widely been utilized as risk calculators to improve the identification of prostate cancer by weighing several clinical factors. The recent inclusion of multiparametric magnetic resonance imaging (mpMRI) findings into nomograms has drastically improved their nomogram's accuracy at identifying clinically significant prostate cancer. Several novel nomograms have incorporated mpMRI to aid in the decision-making process in proceeding with a prostate biopsy in patients who are biopsy-naïve, have a prior negative biopsy, or are on active surveillance. Furthermore, novel nomograms have incorporated mpMRI to aid in treatment planning of definitive therapy. This literature review highlights how the inclusion of mpMRI into prostate cancer nomograms has improved upon their performance, potentially reduce unnecessary procedures, and enhance the individual risk assessment by improving confidence in clinical decision-making by both patients and their care providers.
是否进行前列腺活检的决定必须仔细权衡。诺模图已被广泛用作风险计算器，通过权衡多种临床因素来提高前列腺癌的识别率。最近将多参数磁共振成像（mpMRI）结果纳入诺模图，极大地提高了其在识别临床显著前列腺癌方面的准确性。几种新型诺模图已纳入mpMRI，以帮助在未进行过活检、之前活检结果为阴性或正在进行主动监测的患者中做出是否进行前列腺活检的决策。此外，新型诺模图已纳入mpMRI以辅助确定性治疗的治疗计划。这篇文献综述强调了将mpMRI纳入前列腺癌诺模图如何改善了其性能，可能减少不必要的程序，并通过提高患者及其护理人员对临床决策的信心来增强个体风险评估。
